Evaxion Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Helen Tayton-Martin

Chief executive officer

US$431.0k

Total compensation

CEO salary percentage	8.59%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	2.9yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Mar 11Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Sep 21

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Aug 10

Evaxion Biotech announces new CEO as Lars Wegner resigns

Aug 02

CEO Compensation Analysis

How has Helen Tayton-Martin's remuneration changed compared to Evaxion's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2025	US$431k	US$37k	-US$8m

Compensation vs Market: Helen's total compensation ($USD430.97K) is below average for companies of similar size in the US market ($USD618.25K).

Compensation vs Earnings: Insufficient data to compare Helen's compensation with company performance.

CEO

Helen Tayton-Martin (58 yo)

less than a year

Tenure

US$430,972

Compensation

Dr. Helen Katrina Tayton-Martin, Ph D., MBA, was Chief Business & Strategy Officer of Adaptimmune Therapeutics plc from October 2022 to 2025. She is the Co-Founder of Adaptimmune Therapeutics plc and had b...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Helen Tayton-Martin	Chief Executive Officer	less than a year	US$430.97k	no data
Andreas Mattsson	Founder & Chief AI Officer	18.2yrs	US$364.00k	1.32% $ 389.0k
Thomas Schmidt	Chief Financial Officer	1.3yrs	US$376.00k	0.15% $ 45.5k
Birgitte Rono	Chief Scientific Officer	4.5yrs	US$402.00k	0.0088% $ 2.6k
Benjamin Wolthers	Vice President of Clinical Development	no data	no data	no data

2.9yrs

Average Tenure

54yo

Average Age

Experienced Management: EVAX's management team is considered experienced (2.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Rajeev Surati	Member of Advisory Board	no data	no data	no data
Robert Palay	Member of Advisory Board	no data	no data	no data
Jeffrey Weber	Member of Advisory Board	no data	no data	no data
Soren Brunak	Member of Advisory Board	no data	no data	no data
Michael Washabaugh	Member of Advisory Board	no data	no data	no data
Thomas Wylonis	Member of Advisory Board	no data	no data	no data
Lars Holtug	Independent Director	4.8yrs	US$70.00k	0.062% $ 18.2k
Anthony Purcell	Member of Advisory Board	no data	no data	no data
Andrew Webber	Member of Advisory Board	no data	no data	no data
Marianne Sogaard	Independent Chairwoman of the Board	5.3yrs	US$196.00k	0.93% $ 272.0k
Roberto Pineda	Independent Director	8.2yrs	US$64.00k	0.28% $ 82.4k
Lars Wegner	Director	1.9yrs	US$54.00k	0.031% $ 9.1k

5.1yrs

Average Tenure

57yo

Average Age

Experienced Board: EVAX's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/29 21:27
End of Day Share Price	2026/03/27 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evaxion A/S is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Swayampakula Ramakanth	H.C. Wainwright & Co.
Soumit Roy	JonesTrading Institutional Services, LLC
Thomas Flaten	Lake Street Capital Markets, LLC

Evaxion Management

Management criteria checks 3/4

Key information

Recent management updates

Evaxion A/S, Annual General Meeting, Apr 16, 2026

Evaxion A/S Announces Dr Helen Tayton-Martin Stepping Down from the Board

Evaxion A/S Announces CEO Changes

Evaxion Biotech A/S, Annual General Meeting, Apr 30, 2025

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Recent updates

Evaxion A/S, Annual General Meeting, Apr 16, 2026

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Evaxion A/S Expands AI-Immunology Platform Into Autoimmune Diseases

Evaxion A/S to Report Q3, 2026 Results on Nov 19, 2026

Evaxion A/S to Report Q3, 2025 Results on Nov 06, 2025

Evaxion A/S Announces Dr Helen Tayton-Martin Stepping Down from the Board

Evaxion A/S Announces New Two-Year Unprecedented Clinical Efficacy Data of Its Personalized Cancer Vaccine EVX-01 in Patients with Advanced Melanoma

Evaxion A/S to Present New Biomarker Data for AI- Designed Personalized Cancer Vaccine EVX-01 At the SITC 2025 Annual Meeting

Evaxion A/S to Report Q2, 2025 Results on Aug 14, 2025

Evaxion A/S to Present Two-Year Clinical Efficacy Data from Phase 2 Trial with AI- Designed Personalized Cancer Vaccine EVX-01 at the ESMO Congress 2025

Evaxion A/S Announces CEO Changes

Evaxion Expands R&D Pipeline with New Vaccine Program Targeting Group A Streptococcus

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion A/S to Report Q1, 2025 Results on May 27, 2025

Evaxion Doses First Patient in Extension of Phase 2 Trial Exploring the Full Potential of Ai- Designed Personalized Cancer Vaccine Evx-01

Evaxion Biotech A/S Presents striking EVX-01 Data at the AACR Annual Meeting

Evaxion Biotech A/S, Annual General Meeting, Apr 30, 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $4.48 million.

Evaxion Biotech A/S Extends Phase 2 Trial with AI-Immunology™?

Nasdaq Confirms Evaxion Is Fully Compliant, Withdraws Delisting Determination

Evaxion Completes Dosing in Phase 2 Trial with Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Establishes New AI-Derived Precision Cancer Vaccine Concept

Evaxion Biotech A/S has filed a Follow-on Equity Offering in the amount of $12.5 million.

Evaxion Announces Positive Preclinical Data for Cytomegalovirus (CMV) Vaccine Program EVX-V1

Evaxion Update on Nasdaq Notification Regarding Minimum Stockholders’ Equity Requirement

Evaxion Biotech A/S to Report Q3, 2024 Results on Oct 31, 2024

Evaxion Biotech A/S Announces Strong Validation of Ai-Immunology Platform in Multiple Clinical Trials

Evaxion Biotech A/S Continues to Grows Clinical Evidence for the Steady Improvement of Its Ai-Immunology Platform

Evaxion Biotech A/S Reports Convincing One-Year Data from Phase 2 Trial on AI-Designed Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Reports 69% Overall Response Rate in its Phase 2 Trial on Lead Cancer Vaccine Candidate EVX-01

Consensus revenue estimates increase by 331%

Evaxion Biotech A/S to Report Q2, 2024 Results on Aug 14, 2024

Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Financial position

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Announces Phase 2 Clinical Trial Update

Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Consensus revenue estimates increase by 33%, EPS downgraded

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Forecast to breakeven in 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Negative shareholders equity

Evaxion Biotech A/S to Develop Tailored Novel Cancer Vaccines Based Upon A New Untapped Source of Ai-Discovered Targets

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S Announces Encouraging Initial Phase 2 Clinical Data on its Personalised Cancer Vaccine EVX-01

New and Exciting Clinical Data on Evaxion's Ai-Immunology™?-Based Personalized Cancer Vaccines to Be Presented

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Evaxion Biotech A/S Expands Preclinical Bacterial Vaccine Pipeline in Collaboration with Leading Pharmaceutical Company

Evaxion Biotech A/S Announces New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Evaxion Biotech A/S announced that it expects to receive $20 million in funding from Negma Group Investment Ltd

Evaxion Biotech A/S Plans to Announce the Interim Results of the Clinical Phase 2 Study with EVX-01 in Patients with Metastatic Melanoma in Fourth Quarter 2023

Evaxion Unveils Genetic Adjuvant Technology to Boost Vaccines

Forecast to breakeven in 2024

Evaxion Unveils Proprietary Genetic Aduvant Technology to Boost the Effect of Dna and Mrna Vaccines

Evaxion Biotech A/S, Annual General Meeting, May 24, 2023

Evaxion Biotech A/S and Pantherna Therapeutics GmbH Announce Promising Preclinical mRNA Vaccine Data

Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy

Evaxion Receives Phase IIb Go-Ahead from FDA

Evaxion Biotech A/S Receives Approval from FDA to Proceed with the Clinical Phase 2B Study for Evx-01

Evaxion Biotech Reaches an Important Milestone When Enrolled Its First Patient in Perth, Australia in the Company's Global Phase 2B Clinical Trial of EVX-01

Evaxion Biotech A/S Announces Promising Results from Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy EVX-02

Price target decreased to US$14.67

Evaxion Biotech A/S Welcomes Per Norlén as New CEO

Evaxion Biotech names Per Norlén as CEO

Evaxion Biotech A/S Enrols First Patient in Phase Iib Melanoma Study